



Review of Industry Documents Regarding Dissolvable Tobacco Products: Behavioral Effects

Jeanette Renaud, Ph.D.
Elvira Elek, Ph.D.
Betty Brown, M.P.H.
RTI International

Presented to:
Tobacco Product Scientific Advisory
Committee
Food and Drug Administration
Rockville, MD
January 2012

Purpose

- RTI International identified, reviewed, and summarized industry documents related to behavioral effects of dissolvable tobacco products
- Inform recommendations of the Tobacco Product Scientific Advisory Committee (TPSAC) regarding the use and impact of dissolvable tobacco products on public health
- ***Disclaimer:*** Although the work reported was done under contract with Center for Tobacco Products at FDA, the content and conclusions of this presentation are those of RTI International.

Topic

- **Behavioral Effects** of Dissolvable Tobacco Products
- Looked for information regarding:
 - Initiation
 - Dual use
 - Switching
 - Cessation

Approach

- Three reviewers examined 287 documents submitted to FDA-CTP by 8 tobacco companies
- 63 documents were self-identified as including information relevant to behavioral effects
- 224 *potentially* relevant documents were identified via additional keyword searches, using the following search terms:
 - Initiate/Initiation
 - Dual Use
 - Switch/Switched/Switcher/Switching or Migrate/Migration
 - Cessation or Quit or Abstain/Abstinence

Commerical Confidential Information

- Data reported in the open meeting are limited to information deemed not commerical confidential. The commercial confidential information will be presented to TPSAC SGEs in closed session

Limitations

- Many documents are proposals, protocols, IRB approvals, etc, and therefore, do not include findings
- Short-term clinical trials for test products/concepts